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Screening of genital 
fl uid for Ebola virus 
Moses Soka and colleagues (October, 
2016)1 describe their semen testing 
programme for survivors of Ebola 
virus disease. This programme 
provides an important service to male 
survivors of this disease in Liberia; 
however, we are concerned that the 
real-time RT-PCR assay used might 
not be validated for the detection of 
Ebola virus in semen. Although the 
assay was granted emergency use 
authorisation by the US Food and 
Drug Administration for the detection 
of Ebola virus RNA in blood, plasma, 
serum, and urine, Soka and colleagues 
do not include supporting data for the 
use of this assay with semen. 
W i t h o u t  e s t a b l i s h i n g  t he 
test’s parameters for semen, the 
interpretation of the test results is 
not clear. In our work2 validating a 
different diagnostic platform for 
the detection of Ebola virus RNA in 
semen and vaginal fluid, we found 
that the limits of detection in genital 
fluid were significantly higher than 
in blood. Thus, an undetectable 
result in semen does not necessarily 
mean that there is no Ebola virus in 
the sample—a consideration with 
important implications for sexually 
active male survivors. Additionally, the 
programme only off ers testing to men. 
Because Ebola virus has been detected 
in vaginal fl uid, it is important that 
women should also be given access 
to validated testing of genital fluid 
to empower them with the ability to 
make evidence-based decisions on 
how best to keep their sexual partners 
safe. The screening of genital fluid 
for Ebola virus disease survivors with 
validated diagnostic platforms is a 
much-needed service that should be 
expanded to all men and women who 
survived Ebola virus disease.
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